DBVT

DBVT

USD

DBV Technologies S.A. American Depositary Shares

$14.360+0.310 (2.206%)

Цена в режиме реального времени

Healthcare
Биотехнология
Франция

График цен

Loading Chart...

Ключевые показатели

Рыночные показатели
Фундаментальные показатели компании
Статистические данные торговли

Рыночные показатели

Открытие

$14.050

Максимум

$15.010

Минимум

$14.050

Объем

0.07M

Фундаментальные показатели компании

Рыночная капитализация

521.2M

Отрасль

Биотехнология

Страна

France

Статистические данные торговли

Средний объем

0.10M

Биржа

NCM

Валюта

USD

52-недельный диапазон

Минимум $0.441Текущая $14.360Максимум $18

Связанные новости

GlobeNewswire

DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Châtillon, France, November 4, 2025 DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today

Просмотреть больше
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
GlobeNewswire

DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced the

Просмотреть больше
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
GlobeNewswire

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE

Просмотреть больше
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025
GlobeNewswire

DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors

Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (TRQX:DBVp), (the "Company" or "DBV"), a clinical-stage biopharmaceutical

Просмотреть больше
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
GlobeNewswire

DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting

Châtillon, France, October 30, 2025 DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced upcoming

Просмотреть больше
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting
GlobeNewswire

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq

Châtillon, France, October 29, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (TRQX:DBVp) (the "Company"), a clinical-stage

Analyst Upgrades

HC Wainwright & Co. Maintains Buy on DBV Technologies, Raises Price Target to $20

HC Wainwright & Co. analyst Andrew S. Fein maintains DBV Technologies with a Buy and raises the price target from $16 to $20.

Оставаться в курсе

Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.